The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

The FDA has granted approval for Zydus to proceed with the Phase II(b) trial of Usnoflast for amyotrophic lateral sclerosis (ALS) treatment.

GMP suggested that the stock is expected to list around ₹230. Track live updates on IPO, GMP, subscription status, allotment, ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

Some of its pharma clients, include Aurobindo Pharma, Cadila Pharmaceutical, Granules India Ltd, Macleods Pharmaceuticals, Piramal Pharma, and Suven Pharmaceuticals. IIFL Capital Services Ltd ...

Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker. Merck's cancer drug Keytruda ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The hefty tariffs President-elect Trump has pledged to levy on U.S. imports could impact the price and availability of pharmaceutical drugs. Trump has floated 25 percent tariffs on imports from ...

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...

He has worked with Torrent Pharmaceuticals and Cadila Pharmaceuticals, and also with Reliance Retail and Corporate IT Park. He holds a degree in industrial engineering and is responsible for ...

This scenario indicates that 2025 will be a promising year for the pharma sector. A report by Axis Securities last month outlined a positive outlook for the pharmaceutical sector over the next three ...

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the opening of the first clinical site for its lead asset, HG-CT-1, targeting relapsed ...